Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

  title={Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States},
  author={Catherine Saint-Laurent Thibault and Divya Moorjaney and M. Ganz and B. Sill and S. Hede and Yong Yuan and B. Gorsh},
  journal={Journal of Medical Economics},
  pages={692 - 702}
Abstract Background: A phase III trial evaluated the efficacy and safety of Daklinza (daclatasvir or DCV) in combination with sofosbuvir (SOF) for treatment of genotype (GT) 3 hepatitis C virus (HCV) patients. Aim: This study evaluated the cost-effectiveness of DCV + SOF vs SOF in combination with ribavirin (RBV) over a 20-year time horizon from the perspective of a United States (US) payer. Methods: A published Markov model was adapted to reflect US demographic characteristics, treatment… Expand
12 Weeks of a Ribavirin‐Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation
SOF + NS5A inhibitors without RBV for 12 weeks constituted reliable therapy for recurrent HCV post‐LT with an excellent SVR12 whatever the fibrosis stage, HCV genotype, and previous HCV treatment. Expand
Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702
A thorough review of the model assumptions and model parameters indicates that the relative cost-effectiveness of DCVþ SOF may have been over-estimated, and if data for adherence, relapse, transition probabilities, relevant comparators, and additional population characteristics were considered, more precise cost effectiveness could be obtained. Expand
Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
The baseline distribution of fibrosis and cirrhosis stages that were used, and that are presented in Table 1 of this paper, came from the McGarry et al. article (for all ages). Expand
A Guide to the Economics of Hepatitis C Virus Cure in 2017.
The article provides a foundation of evidence that hepatitis C virus treatment provides good economic value, even though it is expensive, and even when treating people who inject drugs who are at high risk for hepatitis Cirus reinfection. Expand
Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
The model-based evidence suggests that a properly constructed strategy that substantially expands HCV treatment could achieve cost-effective improvements in population health in many countries. Expand
Molecular docking and statistical optimization of taurocholate-stabilized galactose anchored bilosomes for the enhancement of sofosbuvir absorption and hepatic relative targeting efficiency
In vivo results showed that Sofosbuvir availability in the liver was significantly increased after oral administration of the plain and the galactosylated bilosomal formulae when compared to the oral drug solution with relative targeting efficiencies of 1.51 and 3.66, respectively. Expand


Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada
Daclatasvir plus sofosbuvir plus ribavirin is a safe and effective option for the treatment of chronic HCV genotype 3 patients and could be considered a cost-effective option following a first-line treatment of peg-interferon/ribavirin treatment experienced patients with HCV Genotype-3 infection. Expand
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the quality-adjusted life years in treatment-naive patients with chronic HCV genotype 1. Expand
Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.
Results demonstrate that the provision of an alternative, interferon-alfa-free regimen, such as DCV + ASV, offers significant value in terms of avoiding life-threatening liver complications and increasing patients' quality of life. Expand
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
With its high efficacy and improved tolerability, DCV + SOF is an important treatment for hepatitis C genotype 3. Expand
Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial.
These results were robust with combination therapy remaining cost-effective or cost saving in sensitivity analysis involving reasonable variation in all parameters and the higher drug treatment costs nearly completely offset by future savings through reductions in future liver complications from hepatitis C. Expand
The economics of treating chronic hepatitis C patients with peginterferon α‐2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase *
Treatment of PNALT with peginterferon α‐2a (40 kDa) plus ribavirin is projected to reduce the incidence of cirrhosis, increase life expectancy and have an acceptable cost‐effectiveness ratio from a societal perspective. Expand
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
A 12‐week regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated; there were no adverse events leading to discontinuation and only 1 serious AE on‐treatment, which was unrelated to study medications. Expand
Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model
This analysis suggests that the treatment of HCV genotype 1 patients in fibrosis stage F2 has the greatest potential for maximizing health benefit and cost saving within an RGT protocol. Expand
Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C
The principle analysis demonstrates the significant impact on expected costs, LYs and QALYs associated with increasing SVR and validated the robustness of the results reported. Expand
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
A cost-effectiveness analysis was compared with newer regimens containing sofosbuvir for each HCV genotype to evaluate the balance between health benefit and health care expenditures for these treatments under different assumptions about their price and efficacy. Expand